News | May 25, 2022
Piramal Pharma Solutions upgrades Pithampur site
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
The brand has added a range of exciting new products especially formulated for oily skin.
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)